AXSM - CIK 0001579428
Axsome Therapeutics, Inc. trades as AXSM and has a market capitalization of $12.68 B, making it the #813 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $638.50M, up 65.5% from the prior year and net income of -$183.17M. This page tracks Axsome Therapeutics, Inc. through 634 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -374.0% to -28.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-05 |
| 144/A | - | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Insider sale notice | 144 | 2026-05-04 |
| Quarterly report | 10-Q | 2026-05-04 |
| Major company event | 8-K | 2026-05-04 |
| Major company event | 8-K | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-24 |
May 07, 2026 07:00 ET
May 04, 2026 07:00 ET
April 08, 2026 07:00 ET
February 23, 2026 07:00 ET
January 12, 2026 07:00 ET
The largest companies sharing Axsome Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Axsome Therapeutics, Inc. (AXSM) has a market capitalization of $12.68 B as of 2026-06-10, ranking #813 among US-listed companies.
Axsome Therapeutics, Inc. reported revenue of $638.50M for fiscal year 2025, an increase of 65.5% year over year.
In its latest fiscal year Axsome Therapeutics, Inc. reported a net loss of $183.17M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.